In drug development, where you have a very long sequence of filters searching for molecules that treat diseases, the most high-leverage way to reduce R&D costs per *successful* drug is to increase the predictive validity of the early screening steps.
yes, but that's more difficult, because it's partly regulatory and partly intertwined with the high cost of treating patients; one biotech company can't unilaterally reduce costs across the medical system before bringing a drug through trials!
-
-
No, you can't. But I'll note that the overall cost explosion has slowed medical innovation to a crawl. I don't expect individual biotechnology companies to fix this, but it is a major problem for anyone who expects to get sick in their lifetime.
-
I know! I'm continually searching for tractable ways to make progress on the big problem.
- 1 more reply
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.